ClinicalTrials.gg

Program

pimasertib

Also written as “Pimasertib”, “MSC1936369B” and “Pimasertib Capsule (Part A)”.

Its studies are mostly in Neoplasms · Melanoma · Neoplasm Metastasis · Ovarian Neoplasms · Carcinoma, Hepatocellular, led by 3 companies.

Furthest: phase 2, since Aug 11, 200913 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck KGaA, Darmstadt, Germany110 open or runningphase 2since Aug 11, 2009Aug 11, 2009none ahead
Day One Biopharmaceuticals10 open or runningphase 1since Jul 3, 2025Jul 3, 2025none ahead
Sanofi10 open or runningphase 1since May 16, 2011May 16, 2011none ahead

Also a collaborator on its studies: merck-serono-s-a-geneva and merck-serono-co-ltd-japan.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 11, 2009First study: phase 2 study in Leukemia, Myeloid, AcuteNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT00957580 · 81 enrolled · United States, France
  2. Sep 22, 2009Phase 1 study in NeoplasmsMerck KGaA, Darmstadt, Germany · NCT00982865 · 182 enrolled · Australia, Belgium, France and more
  3. Nov 18, 2009Phase 2 study in NeoplasmsMerck KGaA, Darmstadt, Germany · NCT01016483 · 141 enrolled · United States, Germany
  4. Mar 4, 2010Phase 2 study in Colorectal NeoplasmsMerck KGaA, Darmstadt, Germany · NCT01085331 · 16 enrolled · Belgium, Italy, Spain
  5. Apr 18, 2011Phase 1 study in Neoplasm MetastasisMerck KGaA, Darmstadt, Germany · NCT01390818 · 146 enrolled · United States, Italy, Spain
  6. May 16, 2011Sanofi's first study: phase 1 study in Neoplasm MetastasisNew to SanofiSanofi · NCT01357330 · 18 enrolled · United States
  7. Jun 20, 2011Phase 1 study in NeoplasmsMerck KGaA, Darmstadt, Germany · NCT01378377 · 33 enrolled · United States
  8. Aug 15, 2012Phase 1 study in Carcinoma, HepatocellularMerck KGaA, Darmstadt, Germany · NCT01668017 · 26 enrolled · Japan
  9. Sep 13, 2012Phase 1 study in NeoplasmsMerck KGaA, Darmstadt, Germany · NCT01713036 · 6 enrolled · Hungary
  10. Sep 14, 2012Phase 2 study in MelanomaMerck KGaA, Darmstadt, Germany · NCT01693068 · 194 enrolled · United States, Australia, Belgium and more
  11. Aug 23, 2013Phase 2 study in Ovarian NeoplasmsMerck KGaA, Darmstadt, Germany · NCT01936363 · 65 enrolled · United States, Australia, Belgium and more
  12. Nov 8, 2013Phase 1 study in NeoplasmsMerck KGaA, Darmstadt, Germany · NCT01992874 · 38 enrolled · United States
  13. Jul 3, 2025Day One Biopharmaceuticals's first study: phase 1 study in MelanomaNew to Day One BiopharmaceuticalsDay One Biopharmaceuticals · NCT07121829 · 44 enrolled · United States, Canada

TargetBeta

“An orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) ”NCIt, by rule
“Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
cobimetinibruleHoffmann-La Rochephase 338
mirdametinibruleMerck KGaA, Darmstadt, Germanyphase 29
polfurmetinibPfizerphase 13

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07121829Melanoma · United States, Canada1TerminatedDay One BiopharmaceuticalsDec 18, 202444
NCT01992874Neoplasms · United States1CompletedMerck KGaA, Darmstadt, GermanyMay 31, 201438
NCT01936363Ovarian Neoplasms · United States, Australia, Belgium and more2CompletedMerck KGaA, Darmstadt, GermanyMay 31, 201565
NCT01693068Melanoma · United States, Australia, Belgium and more2CompletedMerck KGaA, Darmstadt, GermanyJul 4, 2015194
NCT01713036Neoplasms · Hungary1CompletedMerck KGaA, Darmstadt, GermanyJul 31, 20146
NCT01668017Carcinoma, Hepatocellular · Japan1TerminatedMerck KGaA, Darmstadt, GermanyMay 31, 201526
NCT01378377Neoplasms · United States1TerminatedMerck KGaA, Darmstadt, GermanyFeb 23, 201233
NCT01357330Neoplasm Metastasis · United States1CompletedSanofiJun 201218
NCT01390818Neoplasm Metastasis · United States, Italy, Spain1CompletedMerck KGaA, Darmstadt, GermanyApr 2015146
NCT01085331Colorectal Neoplasms · Belgium, Italy, Spain2TerminatedMerck KGaA, Darmstadt, GermanyApr 201216
NCT01016483Neoplasms · United States, Germany2CompletedMerck KGaA, Darmstadt, GermanyDec 31, 2013141
NCT00982865Neoplasms · Australia, Belgium, France and more1CompletedMerck KGaA, Darmstadt, GermanyMar 31, 2013182
NCT00957580Leukemia, Myeloid, Acute · United States, France2TerminatedMerck KGaA, Darmstadt, GermanyDec 31, 201281

How it is read

Names in the registry

  • “Pimasertib”, 16 entries
  • “MSC1936369B”, 5 entries
  • “Pimasertib Capsule (Part A)”, 2 entries
  • “Pimasertib Tablet (Part A)”, 2 entries
  • “MSC1936369B (pimasertib)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.